Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2024 Earnings Conference Call
February 11, 2025 4:30 PM ET
The Gilead Sciences Q4 2024 Earnings Conference Call took place on February 11, 2025, at 4:30 PM ET. During the call, key members of the company’s leadership team provided insights into the financial performance of Gilead in the fourth quarter and full year of 2024.
Company Participants:
Jacquie Ross – SVP, Treasury & IR
Daniel O’Day – Chairman, CEO
Johanna Mercier – Chief Commercial Officer
Dietmar Berger – Chief Medical Officer
Andrew Dickinson – CFO
Cindy Perettie – EVP, Kite
Conference Call Participants:
Geoff Meacham – Citigroup
Terrence Flynn – Morgan Stanley
Tim Anderson – Bank of America
Umer Raffat – Evercore ISI
Michael Yee – Jefferies
Daina Graybosch – Leerink Partners
Mohit Bansal – Wells Fargo
Brian Abrahams – RBC Capital Markets
Tyler Van Buren – TD Cowen
Ellie Merle – UBS
Courtney Breen – Bernstein
Good afternoon, everyone, and welcome to Gilead’s Fourth Quarter and Full Year 2024 Earnings Conference Call. My name is Rebecca, and I’ll be today’s host.
How will this affect me?
As an investor or stakeholder in Gilead Sciences, the insights shared during the Q4 2024 Earnings Conference Call will provide valuable information on the company’s financial performance, growth strategies, and future outlook. This can help you make informed decisions regarding your investments in Gilead Sciences.
How will this affect the world?
Gilead Sciences is a prominent pharmaceutical company known for its innovative treatments in areas such as HIV, hepatitis C, and oncology. The financial performance and strategic direction discussed in the conference call can have a significant impact on the healthcare industry and the development of new treatments for global health challenges.
Conclusion
The Gilead Sciences Q4 2024 Earnings Conference Call provided valuable insights into the company’s financial performance and strategic direction. As investors, stakeholders, and members of the global community, the information shared during the call will have a ripple effect on decision-making and healthcare advancements in the future.
